Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
US Army
Daiichi Sankyo
Merck
Accenture
UBS
Cipla
Deloitte
US Department of Justice

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203100

« Back to Dashboard

NDA 203100 describes STRIBILD, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from five suppliers. There are sixteen patents protecting this drug. Additional details are available on the STRIBILD profile page.

The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 203100
Tradename:STRIBILD
Applicant:Gilead Sciences Inc
Ingredient:cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
Patents:16
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 203100
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100 NDA A-S Medication Solutions 50090-1318 50090-1318-0 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50090-1318-0)
STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100 NDA State of Florida DOH Central Pharmacy 53808-0887 53808-0887-1 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0887-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG;150MG;200MG;300MG
Approval Date:Aug 27, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 17, 2017
Regulatory Exclusivity Use:EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA
Regulatory Exclusivity Expiration:Aug 27, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Jan 27, 2020
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Expired US Patents for NDA 203100

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 ➤ Subscribe ➤ Subscribe
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Covington
Queensland Health
Boehringer Ingelheim
Farmers Insurance
Express Scripts
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot